Brookstone Capital Management Galectin Therapeutics Inc Transaction History

Brookstone Capital Management

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 14, 2021	SELL	$2.07 - $5.1 $25,999 - $64,055	-12,560 Closed	0 $0
Q1 2021 Apr 16, 2021	SELL	$1.96 - $2.57 $294 - $385	-150 Reduced 1.18%	12,560 $27,000
Q3 2020 Oct 13, 2020	BUY	$2.53 - $3.64 $32,156 - $46,264	12,710 New	12,710 $34,000
Q2 2020 Jul 21, 2020	SELL	$1.66 - $3.15 $16,849 - $31,972	-10,150 Closed	0 $0
Q1 2020 Apr 14, 2020	BUY	$1.51 - $3.0 $15,326 - $30,450	10,150 New	10,150 $20,000

9.69M

1.16M

1.98M

Ticker GALT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,426,000
Market Cap $73.7M
Description
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial f...

Get notified when there are updates to the investment portfolio of Brookstone Capital Management, based on Form 13F filings with the SEC.

Stay updated on Brookstone Capital Management with notifications on news.